Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why ABIOMED Shares Imploded

By Sean Williams - Nov 1, 2012 at 5:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Is this meaningful or just another movement?

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of ABIOMED ( ABMD 4.10% ), a maker of heart support devices, are being absolutely crushed, falling as much as 33% earlier in the trading session, after reporting its second-quarter earnings results.

So what: Surprisingly, ABIOMED's plunge has very little to do with the actual earnings figures themselves -- which came in higher than Wall Street's estimates on an EPS basis -- and almost everything to do with a statement buried beneath its earnings results. In its filing, ABIOMED notes that on Oct. 26, it was informed by the U.S. Attorney's Office for the District of Columbia that it was investigating the company's marketing and labeling practices surrounding its lead revenue-generating device, the Impella 2.5, which pulls blood from the left ventricle of the heart through a catheter, and sends it into the ascending aorta. ABIOMED has pledged to cooperate fully with the investigation.

Now what: The real concern here is that its Impella devices are its primary growth driver. ABIOMED's annual revenue forecast calls for growth of 23%-24%, of which Impella sales are forecast to grow in excess of 30%. If ABIOMED is somehow found guilty of violating marketing or labeling practices, that could cripple its growth prospects. As usual, ABIOMED is innocent until proven guilty but, even after today's tumble, it's still trading at a frothy 32 times forward earnings. This is a case of neat technology, but little substance to the bottom line thus far.

Craving more input? Start by adding ABIOMED to your free and personalized Watchlist so you can keep up on the latest news with the company.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ABIOMED, Inc. Stock Quote
$320.78 (4.10%) $12.63

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.